Legacy Financial Advisors Inc. Makes New $274,000 Investment in GSK PLC Sponsored ADR $GSK

Key Points

• Legacy Financial Advisors Inc. acquired 7,067 shares of GSK PLC Sponsored ADR valued at approximately $274,000 during the first quarter, indicating ongoing institutional interest in the pharmaceutical company.
• GSK recently downgraded its quarterly dividend to $0.4206 per share, representing a 4.2% yield, with a payout ratio of 77.78%.
• Despite recent increases in revenue and earnings per share, GSK has received mixed ratings from analysts, with a consensus price target of $37.38 and the stock currently rated as "Reduce."

Legacy Financial Advisors Inc. acquired a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,067 shares of the pharmaceutical company's stock, valued at approximately $274,000.

Several other institutional investors have also modified their holdings of GSK. Brighton Jones LLC acquired a new stake in shares of GSK in the fourth quarter valued at $528,000. Barclays PLC lifted its holdings in shares of GSK by 84.2% in the fourth quarter. Barclays PLC now owns 49,628 shares of the pharmaceutical company's stock valued at $1,678,000 after buying an additional 22,689 shares during the period. Guggenheim Capital LLC lifted its holdings in shares of GSK by 6.2% in the fourth quarter. Guggenheim Capital LLC now owns 15,053 shares of the pharmaceutical company's stock valued at $509,000 after buying an additional 881 shares during the period. First Trust Advisors LP lifted its holdings in shares of GSK by 8.5% in the fourth quarter. First Trust Advisors LP now owns 1,257,252 shares of the pharmaceutical company's stock valued at $42,520,000 after buying an additional 98,739 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of GSK by 0.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,598,570 shares of the pharmaceutical company's stock valued at $87,884,000 after purchasing an additional 18,492 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Hsbc Global Res raised GSK to a "strong sell" rating in a report on Monday, April 28th. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Finally, Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, GSK presently has a consensus rating of "Reduce" and an average target price of $37.38.

GSK Stock Up 0.5%

GSK stock traded up $0.18 during mid-day trading on Tuesday, hitting $39.82. The company's stock had a trading volume of 978,790 shares, compared to its average volume of 5,113,616. The firm's 50 day moving average is $38.32 and its 200 day moving average is $38.15. The company has a market cap of $81.11 billion, a PE ratio of 18.43, a price-to-earnings-growth ratio of 1.74 and a beta of 0.51. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $44.67.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 4.2%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio is currently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.